Welcome to our dedicated page for TACTILE SYSTEMS TECHNOLOGY SEC filings (Ticker: TCMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tactile Systems Technology, Inc. filings document a Nasdaq-listed medical technology issuer with common stock registered under the ticker TCMD. Recent Form 8-K reports disclose quarterly and annual operating results, financial condition updates, acquisition-related Regulation FD materials, FDA and product-related business highlights, share repurchase authorization activity and other corporate events.
The company's proxy and governance filings cover board composition, director elections, committee assignments, executive compensation, shareholder voting matters and amendments to its certificate of incorporation. Its SEC disclosures also identify Delaware incorporation, Nasdaq listing status, capital actions and governance provisions relevant to its public-company structure.
Tactile Systems Technology Inc (TCMD) received a Rule 144 notice indicating that board member William W. Burke plans to sell restricted shares of the company’s common stock. The notice lists a proposed sale of 11,255 restricted common shares, to be sold for Burke’s account, with Merrill Lynch identified in the securities information section and NASDAQ as the trading market. The notice is dated 08/19/2026 and is signed by Billy Corbellini.
Tactile Systems Technology, Inc. is reported to have a significant shareholder group led by Cadian Capital entities and Eric Bannasch. As of June 30, 2026, they may have been deemed to beneficially own 1,576,940 shares of common stock, representing 7.0% of the 22,701,241 shares outstanding. These shares are held by Cadian Master Fund L.P. and Cadian Opportunities Master Fund LP, over which Cadian Capital Management, LP has exclusive voting and investment power under Investment Management Agreements. The reporting persons have shared voting and dispositive power over all 1,576,940 shares and no sole voting or dispositive power.
Morgan Stanley and its affiliate report reduced ownership in Tactile Systems Technology Inc. (TCMD). Morgan Stanley now reports beneficial ownership of 829,720 shares of TCMD common stock, representing 3.7% of the class, with 823,031 shares subject to shared voting power and all 829,720 shares subject to shared dispositive power.
Morgan Stanley Capital Services LLC separately reports beneficial ownership of 782,920 shares, representing 3.5% of the class, all with shared voting and dispositive power. Both entities state that, as of the reporting date, they have ceased to be beneficial owners of more than five percent of TCMD’s common stock, reclassifying them as holders of 5 percent or less.
Tactile Systems Technology Inc. director and Chief Executive Officer Sheri Louise Dodd reported a sale of 10,978 shares of common stock on August 10, 2026. According to the disclosure, these shares were sold to cover taxes associated with the settlement of stock units at a weighted average price of $29.4446 per share, with individual sale prices ranging from $28.93 to $29.81. After this tax-related sale, Dodd directly holds 232,907 shares of the company’s common stock.
Tactile Systems Technology (Tactile Medical) reported stronger results for Q2 and the first half of 2026. For the quarter ended June 30, 2026, revenue was $85.7 million, up 9% year over year, with six‑month revenue of $161.0 million, up 15%. Lymphedema products drove growth, contributing 86% of Q2 revenue, while airway clearance products represented 14%.
Gross margin was 76% for both the quarter and year‑to‑date, modestly higher than a year earlier. Q2 net income rose to $7.8 million from $3.2 million, and six‑month net income increased to $6.0 million from $0.2 million, helped by operating leverage and much lower interest expense.
The company closed the LymphaTech acquisition (total consideration $12.1 million, including $8.5 million goodwill) to add 3D measurement technology, and signed a three‑year exclusive distribution deal for the MyoSleeve device with a $3.0 million upfront intangible. AffloVest Gen 6 received FDA 510(k) clearance and launched in June 2026. Tactile ended the quarter with $69.9 million in cash, no borrowings on its $40 million revolver, and recognized about $1.0 million of accrual tied to a government False Claims Act settlement.
Tactile Systems Technology, Inc. reported strong results for the quarter ended June 30, 2026. Total revenue rose 9% to $85.7 million from $78.9 million a year earlier, driven by a 12% increase in lymphedema product revenue, partially offset by lower airway clearance sales tied to temporary inventory dynamics around the next-generation AffloVest launch.
Gross profit increased to $65.3 million, with gross margin improving to 76% from 75%. Operating income rose to $6.8 million, and net income grew to $7.8 million, or $0.34 per diluted share, compared to $3.2 million, or $0.14 per share, in the prior-year quarter. Adjusted EBITDA climbed to $11.4 million, up 49% from $7.7 million.
For the first six months of 2026, revenue increased 15% to $161.0 million, with net income of $6.0 million and Adjusted EBITDA of $15.1 million, more than doubling year over year. The company ended June 30, 2026 with $69.9 million in cash and no outstanding borrowings, after repurchasing $5.3 million of stock in the quarter. Full-year 2026 revenue guidance was narrowed to $360–$366 million (9–11% growth), while Adjusted EBITDA guidance was maintained at $49–$51 million.
Tactile Systems Technology, Inc. entered into an exclusive U.S. distribution agreement with ElastiMed, Inc. to distribute the MyoSleeve™ wearable, non-pneumatic compression device to Department of Veterans Affairs and Department of Defense patients across the United States. MyoSleeve, which has U.S. Food and Drug Administration 510(k) clearance for treating chronic swelling conditions, is a discreet, battery-powered lower-leg device designed for earlier stages of disease and as a complement to traditional pneumatic compression therapy.
Under the agreement, Tactile Systems paid $3 million upfront to ElastiMed, obtained exclusive distribution rights within VA and DoD systems, and committed to minimum purchase, marketing, and sales promotion obligations while leveraging its existing sales and patient-support infrastructure to commercialize MyoSleeve.
Tactile Systems Technology Chief Financial Officer Elaine M. Birkemeyer reported an open-market sale of 4,631 shares of common stock on May 11, 2026 at a weighted average price of $24.488 per share. According to the footnotes, these shares were sold to cover taxes associated with the settlement of stock units. After this transaction, she directly holds 130,188 shares of the company’s common stock. The shares were sold in multiple trades with prices ranging from $23.89 to $25.42 per share.
TCMD notice of proposed resale and recent dispositions by an affiliate. The filing lists 4,631 shares of Common Stock proposed for sale by Fidelity Brokerage Services LLC on 05/11/2026 (transaction record shows vesting on 05/08/2026 described as "Restricted Stock Vesting"). The filing also records prior sales of 5,518 shares on 02/23/2026 for $156,142.85 and 7,701 shares on 02/24/2026 for $222,874.64.